Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
CMS proposes to codify the Medicare Drug Price Negotiation Program, which will directly impact pricing and market access for selected drugs. Manufacturers must prepare for mandatory negotiations and potential penalties for non-compliance.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers with high-spend Medicare Part B and Part D drugs, especially those with single-source or limited competition products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Comments due 60 days after publication (around August 15, 2026).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The proposed rule establishes a formal negotiation process for drug prices under Medicare, including selection criteria, negotiation timelines, and maximum fair price (MFP) enforcement. It also introduces penalties for non-compliance, such as excise taxes and civil monetary penalties.
Who it affects
Branded drug makers with high-spend Medicare Part B and Part D drugs, especially those with single-source or limited competition products.
What you must do
Manufacturers must review the proposed rule to understand selection criteria, prepare data for negotiation, and assess potential impact on revenue and market strategy. Submit public comments by the deadline.
Deadline
Comments due 60 days after publication (around August 15, 2026).
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That Prednisolone Tablet, 5 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness